WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of GERON CORP (GERN)

Name GERON CORP
Year low 1.35
Year High 5.24
Symbol GERN
Last trade 2.075
Percentage change 2.72
Volume 1,247,046
Media Volume (3m) 1,518,630
PE Ratio N/A
EPS -1.049
Market Cap 272
Media fatt 2
Trend fatt trend fatt graph for GERON CORP
Media net income 0
Trend net income trend net income for GERON CORP
P / E P / E graph for GERON CORP - 0 points 0
EPS EPS graph for GERON CORP - 0 points 0
MARKET CAP / TOTAL REVENUE market  cap  /  total  revenue  graph for GERON CORP - 0 points 0
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for GERON CORP - 0 points 0
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for GERON CORP - 9 points 9
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for GERON CORP -  points
NET INCOME / MARKET CAP NET  INCOME  /  MARKET  CAP graph for GERON CORP -  points
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for GERON CORP - 0 points 0
NET INC1/NET INC3 net inc1/net inc3 graph for GERON CORP - 8 points 8
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for GERON CORP - 0 points 0
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for GERON CORP - 6 points 6
. . graph for GERON CORP -  points
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for GERON CORP - 2 points 2
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for GERON CORP - 0 points 0
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for GERON CORP - 0 points 0
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for GERON CORP - 1 points 1
. . graph for GERON CORP -  points
SELL HOLD BUY SELL           HOLD          BUY graph for GERON CORP - 0 points 0
SINTESE 26

GRAPHS

max price logarithm graph for GERON CORP based on no conditions max volume linear graph for GERON CORP based on no conditions

News

Geron Completes Enrollment in Phase 2 Clinical Trial of Imetelstat in Breast Cancer (Feb 02 - reuters) More Biotech Lessons Learned From JPM 2012 (Jan 13 - reuters) Ariad: This Bio-Pharma May Deliver Big Returns (Jan 11 - reuters) Geron Corporation Appoints Graham Cooper as Chief Financial Officer (Jan 05 - reuters) Osiris Shows No Reason To Invest In Stem Cell Ideas (Jan 05 - reuters) Geron to Present at the J.P. Morgan Healthcare Conference (Jan 05 - reuters) Micro-Cap Biotech Stocks Legendary Fund Managers Are Accumulating (Jan 04 - reuters) The Worst Health Care Stocks of 2011 (Dec 30 - reuters) Bullish Ideas: Short-Sellers Think These Cash-Rich Companies Have More Upside (Dec 28 - reuters) Geron Is Now A Bargain Buy (Dec 27 - reuters) Health Care's Worst Stocks 2011: Dendreon (Dec 24 - reuters) Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Lung Cancer (Dec 22 - reuters) Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story (Dec 19 - reuters) Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer (Dec 12 - reuters) NeoStem Might Be A Hidden Gem (Dec 07 - reuters) NovaBay May Be In The Right Place At The Right Time With An Answer For Antibiotic Resistance (Dec 02 - reuters) Noteworthy Insider Buys In The Healthcare Sector Last Week (Nov 29 - reuters) Market Volatility = Biotech Opportunity (Nov 22 - reuters) Trade Ideas From Last Week's Big Biotech News Movers (Nov 21 - reuters) Tomorrow's Monster Stock (Nov 17 - reuters) Geron Dumps Stem Cells For Cancer Focus (Nov 17 - reuters) 3 Biotechs Beating the Market (Nov 17 - reuters) The Market Just Crushed My Stock! (Nov 16 - reuters) Other Stem Cell Players Ready To Fill Void Left By Geron (Nov 16 - reuters) Geron Exits Stem Cells To Focus On Oncology (Nov 16 - reuters) Geron's Shift Opens The Door Wide For InVivo (Nov 16 - reuters) UPDATE 1-Geron shares drop on stem cell retreat (Nov 15 - reuters) The Beneficiaries of Geron's Exit From Stem Cell Therapy (Nov 15 - reuters) Geron's Stem Cell Bust Leaves Investors Holding the Bag (Nov 15 - reuters) Geron Presents Final Phase 1 Clinical Data on GRN1005 at AACR-NCI-EORTC (Nov 15 - reuters) Geron to shut down stem cell programs, shares fall (Nov 15 - reuters) Geron to Focus on Its Novel Cancer Programs (Nov 14 - reuters) Regenerative Medicine Universe Earnings Report Card Q3/11 (Nov 11 - reuters) InVivo's Innovative Instigation In Spinal Cord Injury (Nov 11 - reuters) VistaGen Therapeutics Represents Growing Field Of Cell-Based Therapy (Nov 11 - reuters) Geron Reports $19.5M Net Loss In Q3, Says R&D Cost To Rise (Nov 08 - reuters) Geron Corporation Reports 2011 Third Quarter Financial Results and Events (Nov 03 - reuters) Geron And InVivo: The Race To Cure Paralysis (Oct 30 - reuters) Geron Announces Conference Call to Discuss Third Quarter Financial Results and Highlights (Oct 26 - reuters) Geron Announces Presentation At ECTRIMS/ACTRIMS (Oct 25 - reuters) 4 Stocks With Heavy Insider Buying (Oct 25 - reuters) Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial (Oct 20 - reuters) 5 Stocks Under $10 (Oct 17 - reuters) 5 Stocks With Big Insider Buying (Oct 12 - reuters) 3 Contenders To Be The First Profitable Stem Cell Company (Oct 11 - reuters) 3 Companies Leading The Stem Cell Revolution (Oct 11 - reuters) UPDATE 2-Geron names John Scarlett as CEO (Oct 07 - reuters) U.S. firm wins UK embryonic stem cell trial go-ahead (Oct 07 - reuters) StemCells eyes asset sale to raise cash (Oct 07 - reuters) Pioneering UK stem cell trial passes safety test (Oct 07 - reuters)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY